Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

After years of research into xenotransplantation, the field is at a turning point—yet risks and ethical issues remain ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

This study shows that engineered E. coli Nissle 1917 producing indole-3-acetic acid (IAA), an AhR agonist, modulate the tumor ...

The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the demand for gene therapy and genome editing solutions, as these approaches ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $30 price target Intellia is ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...